Univariate analysis (P values) of some outcome variables: discharge to the outpatient clinic, bacteremia, days on intravenous analgesics, days on total parenteral nutrition, acute GVHD grades II-IV, transplantation-related mortality, death, and cost
| Factor (0/1) . | Discharge (> 24 days) . | Bacteremia . | Intravenous analgesics (> 5 days) . | TPN days (> 10 days) . | Acute GVHD II-IV . | TRM . | Death . | Total cost (> US $30 000) . |
|---|---|---|---|---|---|---|---|---|
| Donor (Sib/MUD) | .07 | .08 | ||||||
| SC source (BM/PB) | .03 | |||||||
| Home care (no/yes) | .02 | .12 | .07 | < .01 | .02 | < .01 | < .03 | .01 |
| Diagnosis (others/AL) | ||||||||
| Risk (low/high) | ||||||||
| Recipient sex (M/F) | < .05 | |||||||
| CMV reactivation before discharge (no/yes) | .02 | .03 | .04 | .07 | .02 | |||
| Invasive fungal infection (no/yes) | .06 | |||||||
| Bacteremia (no/yes) | .04 | < .05 | .01 | .03 | .06 | |||
| Acute GVHD II | .20 | < .001 | < .01 | .01 | ||||
| (0-I/II-IV) | ||||||||
| Day of engraftment (continuous) | < .01 | .05 | .02 | .02 | ||||
| Nucleated cell dose (continuous) | .07 | .12 | ||||||
| CMV, recipient and donor (others/neg) | .04 |
| Factor (0/1) . | Discharge (> 24 days) . | Bacteremia . | Intravenous analgesics (> 5 days) . | TPN days (> 10 days) . | Acute GVHD II-IV . | TRM . | Death . | Total cost (> US $30 000) . |
|---|---|---|---|---|---|---|---|---|
| Donor (Sib/MUD) | .07 | .08 | ||||||
| SC source (BM/PB) | .03 | |||||||
| Home care (no/yes) | .02 | .12 | .07 | < .01 | .02 | < .01 | < .03 | .01 |
| Diagnosis (others/AL) | ||||||||
| Risk (low/high) | ||||||||
| Recipient sex (M/F) | < .05 | |||||||
| CMV reactivation before discharge (no/yes) | .02 | .03 | .04 | .07 | .02 | |||
| Invasive fungal infection (no/yes) | .06 | |||||||
| Bacteremia (no/yes) | .04 | < .05 | .01 | .03 | .06 | |||
| Acute GVHD II | .20 | < .001 | < .01 | .01 | ||||
| (0-I/II-IV) | ||||||||
| Day of engraftment (continuous) | < .01 | .05 | .02 | .02 | ||||
| Nucleated cell dose (continuous) | .07 | .12 | ||||||
| CMV, recipient and donor (others/neg) | .04 |
Recipient age, donor age, donor sex, and female donor to male recipient were nonsignificant in all analyses. Sib indicates HLA antigen-identical sibling donor; MUD, matched unrelated donor; PB, peripheral blood stem cells, AL, acute leukemia.